ABBV Jan 2023 140.000 put
- Motley Fool
These 2 Numbers Could Spell Trouble for AbbVie Stock
AbbVie (NYSE: ABBV) investors might have a reason to start sweating. After a somewhat weak first quarter, the biopharma company's near future looks like it'll be one with a bit less revenue than expected.
- PR Newswire
AbbVie Showcases its Leadership in Rheumatology Research with New Data Across Multiple Inflammatory Joint Diseases at the EULAR 2022 Congress
AbbVie (NYSE: ABBV) today announced accepted abstracts and presentations, including three oral presentations, three poster tours and 25 posters, at the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress. The range of data accepted for presentation showcases AbbVie's commitment to discovering and delivering diverse and innovative solutions for the management of rheumatic diseases. The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually.
- Zacks
AbbVie (ABBV) Files NDA for Parkinson's Disease Candidate
AbbVie (ABBV) submits a new drug application to the FDA for ABBV-951, which has been developed for treating advanced Parkinson's disease.
